2 dividends I’d buy before Vodafone Group plc

One Fool has found two yields more attractive than Vodafone’s 5.9%

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Vodafone (LSE: VOD) reported a fall in full-year revenues yesterday after competition in its UK domestic market, as well as key growth market India, intensified. The days of rampant growth seem to be well behind Vodafone and today it’s viewed as a cash cow that pumps out dividends. The shares offer a 5.9% yield, but the cut-throat nature of its industry could result in little accompanying capital appreciation.

Vodafone could be a good income purchase, but I reckon Royal Dutch Shell (LSE: RDSB) and GlaxoSmithKline (LSE: GSK) could be better income picks today.

Smoother cash flows

GlaxoSmithKline’s core operating profit jumped 14% in the first nine months of 2016 and could grow earnings by around 30% in the full year on the back of favourable exchange rates. 

In its last quarter, GSK grew vaccine sales by 20%, and consumer healthcare and pharmaceutical sales by 5% and 6% respectively. Perhaps more importantly, the company’s business model has shifted significantly following the Novartis deal completed nearly two years ago.

Glaxo swapped its oncology business for the Novartis vaccine business before the two pharma giants combined their consumer goods departments in a joint venture, forming a massive operation second in size only to Johnson & Johnson.

I believe this swap could reduce volatility in the company’s cash flows. Oncology tends to be a hit-or-miss business with a cash-hungry R&D element. Vaccines research is expensive, but once developed, the sales are predictable. Most parents will follow doctors orders and vaccinate their children. Novartis was a relatively small-time player in the vaccination world and GSK believes its significant scale in the industry could help squeeze more profit out of the swapped division.

Of course, consumer goods sales are often very stable too. Many of us will buy brands like Voltarol and Sensodyne come economic rain or shine and this defensive quality should also help fortify the dividend in tough times.

That said, the company is still heavily involved in Pharmaceuticals, a far more risky business. On the plus side, the company’s pipeline looks impressive and there’s no patent cliff to deal with. Today, the company yields a whopping 5.2%. Considering its improved business model and recovering cash flows, I believe that could be a bargain.

Can we trust in Shell?

It would be remiss of me to tout Shell as a dividend stalwart without mentioning a major caveat. In spite of being a wonderful operator with an unbroken track record of dividend payments since WW2, Shell’s profits are reliant on the oil price, a factor completely out of its control

Therefore, it could be a pretty risky income buy, as indicated by a 44% profit fall in Q4.

Why would income seekers consider the company after those aforementioned issues? Firstly, the company’s integration of BG is progressing swimmingly, with cost synergies well ahead of plan. Management noted the company was operating “at an underlying cost level that is $10bn lower than Shell and BG combined only 24 months ago“.

As a result, free cash flow-generation increased from £3.32bn in the third quarter to £5.74bn in the fourth quarter demonstrating progress. I believe this figure could recover further as the BG deal begins to bear fruit.

The company currently offers a 6.6% yield. This is well above the market average and, if cash flow improves enough for it to be considered safe, the share price could rise significantly. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zach Coffell owns shares in Royal Dutch Shell B and GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Royal Dutch Shell B. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »